Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Why this approval matters Saxenda was the first GLP-1 drug approved to help with weight loss in the U.S., originally approved in December 2014
HIMS had been getting away with selling compounded injectable semaglutide in a post-shortage regulatory environment for over a year, largely uncontested
Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK, et al
Regulatory and safety landscape Theres a lot of gray market activity
The CREDENCE clinical trial evaluated the effects of canagliflozin 100 mg daily versus placebo in 4401 patients with T2DM and chronic kidney disease (CKD)
Protocol: Reconstitute per the reconstitution guide
US$ 29.50
US$ 28.28
US$ 22.09
US$ 22.24
